Charles Schwab Investment Management Inc Cogent Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 686,697 shares of COGT stock, worth $7.48 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
686,697
Previous 619,036
10.93%
Holding current value
$7.48 Million
Previous $4.16 Million
39.17%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding COGT
# of Institutions
159Shares Held
114MCall Options Held
104KPut Options Held
163K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$114 Million0.24% of portfolio
-
Commodore Capital LP New York, NY9.74MShares$106 Million7.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.26MShares$101 Million6.08% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$79.4 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$75.9 Million8.79% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $717M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...